High-Dose Vitamin C to Treat Cancer

Created on 10/31/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

High-dose vitamin C is a vitamin repeatedly infused intravenously, reaching blood levels food or oral supplements cannot, as an add-on to cancer treatment. Evidence is mixed: some studies point toward longer survival, but the largest trial showed no overall gain. Screened patients generally tolerate it; kidney damage, red blood cell destruction and misleading fingerstick glucose readings are uncommon but serious. Abandoning proven treatment carries the greatest risk. (Full Review)

Protocol

Academic fixed-dose regimen (University of Iowa)
75–87.5 g three times weekly
75 g with gemcitabine and nab-paclitaxel; 87.5 g during radiation for glioblastoma, then twice weekly, targeting at least 20 mM
Weight-based regimens
1–1.5 g/kg
1.5 g/kg three times weekly, or daily on days 1–3 every 2 weeks with FOLFOX; 1 g/kg with docetaxel
Titration
25 g starting dose
Bladder cancer trial dosing, titrated to a target blood level; common practice checks post-infusion vitamin C levels after escalation
Time to effect
Survival
Months
Seen in trials; unproven across cancers
Quality of life
Within one week
Uncontrolled reports only; no difference vs placebo in a controlled trial

Benefits

Contraindications
  • G6PD deficiency
  • Kidney impairment or history of oxalate kidney stones
  • Pregnancy and lactation
  • Iron overload (transfusion-related overload in thalassemia, hereditary hemochromatosis)
  • Heart failure or required sodium restriction
Key Interactions
  • Point-of-care glucose meters and urine dipsticks
  • Antibiotics (erythromycin, doxycycline) and bleomycin
  • Amphetamine and urine-pH-sensitive drugs (fluphenazine)
  • Warfarin
  • Antiretrovirals (e.g., indinavir)
  • Deferoxamine
  • Iron supplements and intravenous iron
  • High-dose oral vitamin C supplements
  • Acetaminophen (paracetamol)
Theoretical (inferred from mechanism)
  • Bortezomib and ixazomib (proteasome inhibitors)
  • Nephrotoxic drugs (cisplatin, methotrexate) and NSAIDs (such as ibuprofen, naproxen)
  • Oxidant drugs (rasburicase, dapsone)
  • Antioxidant supplements (N-acetylcysteine, high-dose vitamin E)
  • Alpha-lipoic acid infusions

Risk & Side Effects

  • High:
  • Medium: False Readings on Glucose Meters and Lab Tests
  • Low: Oxalate Kidney Injury and Kidney Stones; Hemolysis in G6PD Deficiency; Worse Outcomes in Critical Illness; Delayed or Forgone Effective Cancer Treatment; Reduced Chemotherapy Effectiveness; Minor Infusion-Related Effects
  • Speculative: Selection of More Aggressive Resistant Tumor Cells

Monitoring

Marker Target Why
G6PD activity Normal activity per laboratory Safety: deficiency stops or limits use
Serum creatinine About 0.6–1.2 mg/dL Safety: rising values pause use
Peak plasma vitamin C At least 20 mM after infusion Confirms target blood level
Hemoglobin and bilirubin Hemoglobin about 12–17.5 g/dL; total bilirubin about 0.1–1.2 mg/dL Safety: signals hemolysis
Lactate dehydrogenase Not specified in the ER Paired hemolysis check
Serum sodium and potassium Sodium 135–145 mmol/L; potassium 3.5–5.0 mmol/L Safety: sodium load from sodium ascorbate
Ferritin and transferrin saturation Ferritin about 20–300 ng/mL; transferrin saturation about 20–50% Safety: iron overload stops or changes use
Laboratory venous glucose Fasting 70–99 mg/dL Safety: replaces unreliable meters
Tumor markers and imaging No established target; change from own baseline Disease control

Cadence: Baseline before the first infusion (G6PD once); creatinine and electrolytes before each infusion for the first 2 weeks, then every 2–4 weeks; post-infusion vitamin C level after each dose step until the target is reached; complete blood count every 2–4 weeks or immediately if urine darkens; tumor markers or imaging every 2–3 months.

Qualitative Assessment

  • Energy level and fatigue across the week after infusions
  • Appetite, nausea and tolerance of chemotherapy cycles
  • Pain levels and need for pain medication
  • Infusion-site comfort, thirst and urine color
  • Ability to keep up daily activities and exercise